Doravirine and Islatravir Have Complementary Resistance Profiles and Create a Combination with a High Barrier to Resistance-Reference-Cited by-同舟云学术

Doravirine and Islatravir Have Complementary Resistance Profiles and Create a Combination with a High Barrier to Resistance

Published:2022-05-17 Issue:5 Volume:66 Page:
ISSN:0066-4804
Container-title:Antimicrobial Agents and Chemotherapy
language:en
Short-container-title:Antimicrob Agents Chemother

Author:

Lai Ming-Tain¹,Feng Meizhen¹,Xu Min²,Ngo Winnie¹,Diamond Tracy L.¹^ORCID,Hwang Carey³,Grobler Jay A.¹,Hazuda Daria J.¹,Asante-Appiah Ernest¹^ORCID

Affiliation:

1. Infectious Diseases and Vaccines, Merck & Co., Inc., Kenilworth, New Jersey, USA

2. Quantitative Biosciences, Merck & Co., Inc., Kenilworth, New Jersey, USA

3. Global Clinical Development, Merck & Co., Inc., Kenilworth, New Jersey, USA

Abstract

Doravirine (DOR), a non-nucleoside reverse transcriptase inhibitor (NNRTI), was approved for treatment of HIV-1 infection in 2018. In the pivotal phase 3 trials, DRIVE-FORWARD and DRIVE-AHEAD, 7 out of 747 (0.9%) treatment-naive participants treated with DOR plus two nucleos(t)ide reverse transcriptase inhibitors (NRTIs) met protocol-defined virologic failure criteria and showed phenotypic resistance to DOR at week 48.

Publisher

American Society for Microbiology

Subject

Infectious Diseases,Pharmacology (medical),Pharmacology

Link

https://journals.asm.org/doi/pdf/10.1128/aac.02223-21

Reference28 articles.

1. Structure and Function of HIV-1 Reverse Transcriptase: Molecular Mechanisms of Polymerization and Inhibition

2. HIV-1 Reverse Transcription

3. HIV-1 Reverse Transcriptase: A Therapeutical Target in the Spotlight

4. Evolving understanding of HIV-1 reverse transcriptase structure, function, inhibition, and resistance

5. Crystal Structure at 3.5 Å Resolution of HIV-1 Reverse Transcriptase Complexed with an Inhibitor

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Islatravir: evaluation of clinical development for HIV and HBV;Expert Opinion on Investigational Drugs;2024-01-18

2. HIV drug resistance in the era of contemporary antiretroviral therapy: A clinical perspective;Antiviral Therapy;2023-09-25

3. An update on long-acting agents in HIV therapy;Future Virology;2023-09

4. Doravirine responses to HIV-1 viruses bearing mutations to NRTIs and NNRTIs under in vitro selective drug pressure;Journal of Antimicrobial Chemotherapy;2023-06-12

5. Residual phenotypic susceptibility to doravirine in multidrug-resistant HIV-1 from subjects enrolled in the PRESTIGIO Registry;International Journal of Antimicrobial Agents;2023-03